126 related articles for article (PubMed ID: 8827870)
1. [Multidrug resistance in acute leukemia].
Takeshita A; Ohno R
Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
[TBL] [Abstract][Full Text] [Related]
2. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells.
Takeshita A; Shinjo K; Ohnishi K; Ohno R
Br J Haematol; 1996 Apr; 93(1):18-21. PubMed ID: 8611458
[TBL] [Abstract][Full Text] [Related]
3. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
4. New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate.
Takeshita A; Shinjo K; Ohnishi K; Ohno R
Jpn J Cancer Res; 1995 Jun; 86(6):607-15. PubMed ID: 7622426
[TBL] [Abstract][Full Text] [Related]
5. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
7. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
8. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
[TBL] [Abstract][Full Text] [Related]
9. CD34+/CD33+ blast cells: correlation with FAB subtypes.
Rigolin GM; Lanza F; Ferrari L; Castoldi G
Leuk Lymphoma; 1995; 18 Suppl 1():43-8. PubMed ID: 7496354
[TBL] [Abstract][Full Text] [Related]
10. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
11. [Immunophenotypic features in 143 cases of acute promyelocytic leukemia].
Sun HM; Qian SX; Wu YJ; Qiao C; Hong M; Fan L; Yang H; Zhang JF; Zhang SJ; Wu HX; Qiu HX; Lu H; Xu W; Sheng RL; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):176-9. PubMed ID: 19236773
[TBL] [Abstract][Full Text] [Related]
12. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
13. Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Imrichova D; Messingerova L; Seres M; Kavcova H; Pavlikova L; Coculova M; Breier A; Sulova Z
Eur J Pharm Sci; 2015 Sep; 77():29-39. PubMed ID: 26002042
[TBL] [Abstract][Full Text] [Related]
14. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.
Drach D; Zhao S; Drach J; Mahadevia R; Gattringer C; Huber H; Andreeff M
Blood; 1992 Dec; 80(11):2729-34. PubMed ID: 1360266
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia.
Lanza F; Rigolin GM; Moretti S; Latorraca A; Castoldi G
Leuk Lymphoma; 1994; 13 Suppl 1():81-5. PubMed ID: 7521238
[TBL] [Abstract][Full Text] [Related]
16. Differences in CD33 intensity between various myeloid neoplasms.
Jilani I; Estey E; Huh Y; Joe Y; Manshouri T; Yared M; Giles F; Kantarjian H; Cortes J; Thomas D; Keating M; Freireich E; Albitar M
Am J Clin Pathol; 2002 Oct; 118(4):560-6. PubMed ID: 12375643
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
18. Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia.
Oka S; Muroi K; Matsuyama T; Sato K; Ueda M; Toshima M; Suzuki T; Ozaki K; Mori M; Takubo T; Nagai T; Hanafusa T; Ozawa K
Hematology; 2009 Jun; 14(3):133-8. PubMed ID: 19490757
[TBL] [Abstract][Full Text] [Related]
19. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
[TBL] [Abstract][Full Text] [Related]
20. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
